QLIFE
QLIFE HOLDING AB, Interim Report Q2, April - June 2026
Building Momentum Through Partnerships and Innovation
Bolag
QLife
Qlife Holding är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret beläget i Helsingborg.
Senaste nyheter och pressmeddelanden
QLIFE
Qlife Holding AB – Business Update, First Half of 2026
Qlife Holding AB ("Qlife" or the "Company") is pleased to provide a business update for the first half of 2026. During the period, the Company has continued to advance multiple strategic partnership initiatives across both the pharmaceutical and diagnostics sectors, while maintaining steady progress on its Egoo Health platform and regulatory milestones.
QLIFE
Qlife enters fully funded feasibility agreement with global pharma company for Egoo Health biomarker application
Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, announces that it has entered into a feasibility agreement with a global pharmaceutical company with the objective to evaluate a specific biomarker on Egoo Health related to a therapeutic application. The feasibility agreement is fully funded by the pharma company.
QLIFE
Kommuniké från årsstämma 2026 i Qlife Holding AB
Qlife Holding AB höll den 27 maj 2026 årsstämma varvid i huvudsak följande beslut fattades.
QLIFE
QLIFE HOLDING AB, Interim Report Q1, January - March 2026
Approaching strategic partnerships
QLIFE
Qlife Holding AB publicerar årsredovisning för 2025
Qlife Holding AB:s (“Qlife”) årsredovisning finns från och med idag tillgänglig på Qlifes hemsida: https://qlifeholding.com/sv/investerare/finansiella-rapporter.
QLIFE
Kallelse till årsstämma 2026 i Qlife Holding AB
Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till årsstämma den 27 maj 2026 kl. 11.00 i Moll Wendén Advokatbyrås lokaler på Stortorget 8 i Malmö.
QLIFE
The ISP leaves notifications under the FDI Act without action in connection with allotment to certain investors in Qlife's rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE
QLIFE
Qlife announces the last day of trading in BTA
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE
QLIFE
Qlife announces the outcome of the rights issue and resolves on a directed issue of shares to guarantors
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE
QLIFE
Qlife provides business update on clinical progress, partnerships and commercialization initiatives
Qlife Holding AB (“Qlife” or the “Company”), a pioneer in clinical-grade home diagnostics, today provides a business update covering recent milestones, ongoing progress, and priorities for the coming quarters.
QLIFE
The subscription period in Qlife’s rights issue ends on Thursday, 19 March 2026
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE